Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placeboPAP · people with pulmonary hypertension due to left‐heart disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 130 participantsModerate